After finishing at $16.78 in the prior trading day, TG Therapeutics Inc (NASDAQ: TGTX) closed at $16.37, down -2.44%. In other words, the price has decreased by -$0.41 from its previous closing price. On the day, 3392522 shares were traded.
Ratios:
Our goal is to gain a better understanding of TGTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.92. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 02, 2023, Upgraded its rating to Neutral and sets its target price to $12 from $16 previously.
On May 20, 2022, BofA Securities started tracking the stock assigning a Underperform rating and target price of $5.BofA Securities initiated its Underperform rating on May 20, 2022, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’24 when Charney Laurence N sold 17,500 shares for $19.03 per share. The transaction valued at 333,025 led to the insider holds 237,229 shares of the business.
Power Sean A sold 47,867 shares of TGTX for $809,431 on Jan 03 ’24. The CFO now owns 606,969 shares after completing the transaction at $16.91 per share. On Aug 11 ’23, another insider, WEISS MICHAEL S, who serves as the CEO and President of the company, bought 100,000 shares for $10.13 each. As a result, the insider paid 1,013,000 and bolstered with 12,073,021 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 2.59B and an Enterprise Value of 2.48B. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1160.99, and their Forward P/E ratio for the next fiscal year is 37.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.82 while its Price-to-Book (P/B) ratio in mrq is 15.44. Its current Enterprise Value per Revenue stands at 10.63 whereas that against EBITDA is 95.19.
Stock Price History:
Over the past 52 weeks, TGTX has reached a high of $35.67, while it has fallen to a 52-week low of $6.46. The 50-Day Moving Average of the stock is 16.12, while the 200-Day Moving Average is calculated to be 15.26.
Shares Statistics:
The stock has traded on average 5.21M shares per day over the past 3-months and 5.68M shares per day over the last 10 days, according to various share statistics. A total of 151.42M shares are outstanding, with a floating share count of 139.12M. Insiders hold about 9.91% of the company’s shares, while institutions hold 58.93% stake in the company. Shares short for TGTX as of Feb 15, 2024 were 35.78M with a Short Ratio of 6.86, compared to 30.7M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 23.63% and a Short% of Float of 29.09%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of $0.05 and a low estimate of -$0.12, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.01 and low estimates of -$0.15.
Analysts are recommending an EPS of between $0.18 and -$0.51 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is $0.48, with 7 analysts recommending between $0.93 and -$0.1.
Revenue Estimates
7 analysts predict $54.58M in revenue for the current quarter. It ranges from a high estimate of $59M to a low estimate of $46M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $7.8M, an estimated increase of 599.50% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $56.56M, an increase of 224.10% less than the figure of $599.50% in the same quarter last year. There is a high estimate of $59.4M for the next quarter, whereas the lowest estimate is $52.11M.
A total of 8 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $325.28M, while the lowest revenue estimate was $239.76M, resulting in an average revenue estimate of $263.85M. In the same quarter a year ago, actual revenue was $233.66M, up 12.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $412.69M in the next fiscal year. The high estimate is $540.3M and the low estimate is $326.92M. The average revenue growth estimate for next year is up 56.40% from the average revenue estimate for this year.
